Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
2.230
-0.090 (-3.88%)
At close: Mar 27, 2026, 4:00 PM EDT
2.182
-0.048 (-2.14%)
After-hours: Mar 27, 2026, 7:59 PM EDT
Editas Medicine Revenue
In the year 2025, Editas Medicine had annual revenue of $40.52M with 25.39% growth. Editas Medicine had revenue of $24.74M in the quarter ending December 31, 2025, a decrease of -19.16%.
Revenue (ttm)
$40.52M
Revenue Growth
+25.40%
P/S Ratio
5.39
Revenue / Employee
$465,747
Employees
87
Market Cap
218.25M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 40.52M | 8.21M | 25.39% |
| Dec 31, 2024 | 32.31M | -45.81M | -58.64% |
| Dec 31, 2023 | 78.12M | 58.41M | 296.32% |
| Dec 31, 2022 | 19.71M | -5.83M | -22.83% |
| Dec 31, 2021 | 25.54M | -65.19M | -71.85% |
| Dec 31, 2020 | 90.73M | 70.20M | 341.93% |
| Dec 31, 2019 | 20.53M | -11.41M | -35.71% |
| Dec 31, 2018 | 31.94M | 18.21M | 132.64% |
| Dec 31, 2017 | 13.73M | 7.68M | 126.80% |
| Dec 31, 2016 | 6.05M | 4.42M | 271.58% |
| Dec 31, 2015 | 1.63M | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Keros Therapeutics | 244.06M |
| Cellectis | 79.59M |
| Voyager Therapeutics | 40.37M |
| Alector | 21.05M |
| Sol-Gel Technologies | 19.39M |
| OmniAb | 18.67M |
| Camp4 Therapeutics | 3.50M |
| Inhibikase Therapeutics | 1.00 |
EDIT News
- 15 hours ago - Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference - GlobeNewsWire
- 15 days ago - Editas Medicine, Inc. (EDIT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript - Seeking Alpha
- 18 days ago - Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates - GlobeNewsWire
- 4 weeks ago - Editas Medicine to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Genflow Biosciences PLC Announces Directorate Change - Accesswire
- 4 months ago - Editas Medicine Announces Third Quarter 2025 Results and Business Updates - GlobeNewsWire
- 5 months ago - Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025 - GlobeNewsWire
- 5 months ago - Editas Medicine: Three Strikes And It's Out, Or Third Time's The Charm? - Seeking Alpha